IgG Antibody Responses and Immune Persistence of Two Doses of BBIBP-CorV Vaccine or CoronaVac Vaccine in People Living with HIV (PLWH) in Shenzhen, China
出版年份 2022 全文链接
标题
IgG Antibody Responses and Immune Persistence of Two Doses of BBIBP-CorV Vaccine or CoronaVac Vaccine in People Living with HIV (PLWH) in Shenzhen, China
作者
关键词
-
出版物
Vaccines
Volume 10, Issue 6, Pages 880
出版商
MDPI AG
发表日期
2022-05-31
DOI
10.3390/vaccines10060880
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China
- (2022) Xiaojie Huang et al. Viruses-Basel
- Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study
- (2022) Jingwen Ai et al. Emerging Microbes & Infections
- Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine
- (2022) Yihao Liu et al. Cell Discovery
- Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2
- (2022) María Noel Badano et al. MOLECULAR IMMUNOLOGY
- Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
- (2022) Ling Ao et al. Emerging Microbes & Infections
- Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study
- (2022) Lucas C Netto et al. Lancet HIV
- Factors Influencing Level and Persistence of Anti SARS-CoV-2 IgG after BNT162b2 Vaccine: Evidence from a Large Cohort of Healthcare Workers
- (2022) Cristina Costa et al. Vaccines
- Anti-SARS-CoV-2 Antibody Responses 5 Months Post Complete Vaccination of Moroccan Healthcare Workers
- (2022) Najlaa Assaid et al. Vaccines
- COVID-19 Vaccines for HIV-Infected Patients
- (2021) Maria M. Plummer et al. Viruses-Basel
- SARS-CoV-2 Spike Antibody Levels Trend among Sinopharm Vaccinated People
- (2021) Umar Saeed et al. Iranian Journal of Public Health
- Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
- (2021) John Frater et al. Lancet HIV
- Transient increase in plasma HIV RNA after COVID-19 vaccination with mRNA-1272
- (2021) Giorgio Bozzi et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials
- (2021) Gang Zeng et al. LANCET INFECTIOUS DISEASES
- COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity
- (2021) Ying Liu et al. Vaccines
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
- (2020) Shengli Xia et al. LANCET INFECTIOUS DISEASES
- Sharing CD4+ T Cell Loss: When COVID-19 and HIV Collide on Immune System
- (2020) Xiaorong Peng et al. Frontiers in Immunology
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- (2020) Yanjun Zhang et al. LANCET INFECTIOUS DISEASES
- Germinal centers B-cell reaction and T follicular helper cells in response to HIV-1 infection
- (2019) Raphaël Jeger-Madiot et al. Current Opinion in HIV and AIDS
- Long-term Immune Responses to Vaccination in HIV-Infected Patients: A Systematic Review and Meta-Analysis
- (2014) S. Kerneis et al. CLINICAL INFECTIOUS DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started